TIDMERGO

RNS Number : 5208I

Ergomed plc

05 December 2022

Director Dealing

Guildford, UK - 5 December 2022 : Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces that on 2 December 2022, Richard Barfield, Chief Financial Officer of Ergomed, exercised options under the Company's Long Term Incentive Plan and sold the shares issued by the Company pursuant to such exercise. Mr Barfield exercised options over 125,000 ordinary shares of GBP0.01 each in the Company ("Ordinary Shares") at an exercise price of GBP0.01 per share and subsequently sold 125,000 Ordinary Shares at a price of GBP13.45 per share.

Following this sale, Richard Barfield holds 25,000 Ordinary Shares representing 0.05% of the Company's issued share capital.

The notification set out below is provided in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.

 
 1     Details of the person discharging managerial responsibilities/person 
        closely associated 
 a)    Name                               Richard Barfield 
      ---------------------------------  ------------------------------------------------- 
 2     Reason for the notification 
      ------------------------------------------------------------------------------------ 
 a)    Position/status                    Chief Financial Officer 
      ---------------------------------  ------------------------------------------------- 
 b)    Initial notification               Initial Notification 
        /Amendment 
      ---------------------------------  ------------------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ------------------------------------------------------------------------------------ 
 a)    Name                               Ergomed plc 
      ---------------------------------  ------------------------------------------------- 
 b)    Legal Entity                       213800BVS8I9VMC1AP84 
        Identifier 
      ---------------------------------  ------------------------------------------------- 
 4     Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      ------------------------------------------------------------------------------------ 
 a)    Description                        Ordinary shares of 1 pence each 
        of the financial 
        instrument, 
        type of instrument                 GB00BN7ZCY67 
        Identification 
        code 
      ---------------------------------  ------------------------------------------------- 
 b)    Nature of the                      Exercise of share options under the Company's 
        transaction                        Long Term Incentive Plan 
      ---------------------------------  ------------------------------------------------- 
 c)    Currency                           GBP 
      ---------------------------------  ------------------------------------------------- 
 d)    Price(s) and                                 Price(s)                 Volume(s) 
        volume(s) 
      ---------------------------------  -----------------------------  ------------------ 
                             Exercise price 
                                 GBP0.01                                      125,000 
  --------------------------------------------------------------------  ------------------ 
 
 e)    Aggregated 
        information 
 
        - Aggregated 
        volume                              n/a 
 
        - Price 
 
        - Aggregated 
        total 
      ---------------------------------  ------------------------------------------------- 
 f)    Date of the                        2 December 2022 
        transaction 
      ---------------------------------  ------------------------------------------------- 
 g)    Place of the                       London Stock Exchange, AIM 
        transaction 
      ---------------------------------  ------------------------------------------------- 
 
 
 1     Details of the person discharging managerial responsibilities/person 
        closely associated 
 a)    Name                                    Richard Barfield 
      --------------------------------------  ----------------------------------- 
 2     Reason for the notification 
      --------------------------------------------------------------------------- 
 a)    Position/status                         Chief Financial Officer 
      --------------------------------------  ----------------------------------- 
 b)    Initial notification                    Initial Notification 
        /Amendment 
      --------------------------------------  ----------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      --------------------------------------------------------------------------- 
 a)    Name                                    Ergomed plc 
      --------------------------------------  ----------------------------------- 
 b)    Legal Entity                            213800BVS8I9VMC1AP84 
        Identifier 
      --------------------------------------  ----------------------------------- 
 4     Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      --------------------------------------------------------------------------- 
 a)    Description                             Ordinary shares of 1 pence each 
        of the financial 
        instrument, 
        type of instrument                      GB00BN7ZCY67 
        Identification 
        code 
      --------------------------------------  ----------------------------------- 
 b)    Nature of the                           Sale 
        transaction 
      --------------------------------------  ----------------------------------- 
 c)    Currency                                GBP 
      --------------------------------------  ----------------------------------- 
 d)    Price(s) and                               Price(s)          Volume(s) 
        volume(s) 
      --------------------------------------  ----------------  ----------------- 
                            GBP13.45                                 125,000 
  ------------------------------------------------------------  ----------------- 
 
 e)    Aggregated 
        information 
 
        - Aggregated                             125,000 
        volume                                   GBP13.45 
                                                 GBP1,681,250 
        - Price 
 
        - Aggregated 
        total 
      --------------------------------------  ----------------------------------- 
 f)    Date of the                             2 December 2022 
        transaction 
      --------------------------------------  ----------------------------------- 
 g)    Place of the                            London Stock Exchange, AIM 
        transaction 
      --------------------------------------  -----------------------------------

ENDS

Enquiries :

Ergomed plc Tel: +44 (0) 1483 402 975

Dr Miroslav Reljanović (Executive Chairman)

Richard Barfield (Chief Financial Officer)

Keith Byrne (Senior Vice-President, Capital Markets & Strategy)

Numis Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Euan Brown (Nominated Adviser)

James Black (Broker)

Peel Hunt LLP Tel: +44 (0) 20 7418 8900

James Steel / Dr Christopher Golden

   Consilium Strategic Communications                                       Tel: +44 (0) 20 3709 5700

Chris Gardner / Matthew Neal ergomed@consilium-comms.com

Angela Gray

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHUPGPPPUPPGBC

(END) Dow Jones Newswires

December 05, 2022 02:00 ET (07:00 GMT)

Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Ergomed.
Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Ergomed.